General information about company

Scrip code*540204
NSE Symbol*NOTLISTED
MSEI Symbol*NOTLISTED
ISIN*INE666Q01016
Name of companyEIKO LIFESCIENCES LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2026
Date of end of financial year31-03-2027
Date of board meeting when results were approved12-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange07-08-2026
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterFirst quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment ReportingSingle segment
Description of single segmentSpecialty & fine chemicals
Start date and time of board meeting12-08-2026 13:00
End date and time of board meeting12-08-2026 13:40
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?Yes
No. of times funds raised during the quarter1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?NoNo Such default in Loans and not listed on Debt Exchange



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202601-04-2026
Date of end of reporting period30-06-202630-06-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations1417.811417.81
Other income68.3468.34
Total income1486.151486.15
2Expenses
(a)Cost of materials consumed1324.51324.5
(b)Purchases of stock-in-trade00
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-40.96-40.96
(d)Employee benefit expense 7.167.16
(e)Finance costs4.064.06
(f)Depreciation, depletion and amortisation expense14.7414.74
(g)Other Expenses
1Other Expenses36.2136.21
Total other expenses36.2136.21
Total expenses1345.711345.71
3Total profit before exceptional items and tax140.44140.44
4Exceptional items 00
5Total profit before tax140.44140.44
6Tax expense
7Current tax32.6532.65
8Deferred tax1.361.36
9Total tax expenses34.0134.01
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations106.43106.43
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period106.43106.43
17Other comprehensive income net of taxes00
18Total Comprehensive Income for the period106.43106.43
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital1434.591434.59
Face value of equity share capital1010
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations0.740.74
Diluted earnings (loss) per share from continuing operations0.620.62
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations0.740.74
Diluted earnings (loss) per share from continuing and discontinued operations0.620.62
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Other Comprehensive Income

Date of start of reporting period01-04-202601-04-2026
Date of end of reporting period30-06-202630-06-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2Income tax relating to items that will not be reclassified to profit or loss 0.000.00
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income0.000.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund RaisingPreferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds24-02-2026
Amount Raised405.62
Report filed for Quarter ended30-06-2026
Monitoring AgencyNot applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raisedNo
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / VariationNot Applicable
Comments of the Audit Committee after reviewThe Company has allotted 29,50,000 (Twenty Nine Lakh Fifty Thousand) Warrants convertible into equivalent number of Equity Shares to the persons belonging to Promoter and Promoter Group on Preferential Basis, at an issue price of Rs. 55/- per warrant, including premium of Rs. 45/- per warrant, against which 25% of the consideration has been received on application, dated 24 February, 2026. In Current quarter no conversion of warrant has been done.
Comments of the auditors, if anyNone


Signatory Details

Name of signatoryChintan Doshi
Designation of personCompany Secretary and Compliance Officer
PlaceThane
Date12-08-2026